

REMARKS

In the instant Office Action, claims 1-22 are listed as pending and all claims are subject to a restriction requirement under 35 U.S.C 121.

The Examiner alleges that the following groups of claims define patentably-distinct inventions:

- I. Claims 1-19, drawn to methods of screening for compounds that bind to the somatostatin type-5 receptor and inhibit amylin release, classified in Class 435, subclass 7.21; and
- II. Claims 20-22, drawn to a method of treating hyperamylinemia comprising administering a somatostatin type-5 agonist, classified in Class 514, subclass 2.

The details supporting the Examiner's reasons for the restriction requirement can be found on pages 2 and 3 of the instant Action and are not reiterated in full in this reply.

Applicants elect, without traverse, the claims of Group I, namely claims Claims 1-19, drawn to methods of screening for compounds that bind to the somatostatin type-5 receptor and inhibit amylin release.

Reconsideration of the instant Office Action, entry of the amendments submitted herewith, and allowance of all pending claims are respectfully requested. Prompt and favorable action is solicited.

Respectfully submitted,

Date:

10/27/06

Pamela C Ball

Pamela C. Ball
Agent for Applicant(s)
Reg. No. 53,963

Biomeasure, Incorporated
27 Maple Street
Milford, MA 01757-3650
(508) 478-0144 Telephone
(508) 473-3531 Facsimile